# Platinum Asia Investments Limited ASX: PAI

## MONTHLY REPORT 31 May 2022

## **FACTS**

Portfolio value	\$373.37 mn
Portfolio commenced	15 September 2015
Current share price	\$0.855
Current dividend yield	9.94%
Pre-tax NTA	\$1.0135
Post-tax NTA	\$1.0453
Maximum franked dividend	9.95 cps
NTA retained earnings & div profit resv.	5.34 cps
4	

### PERFORMANCE 1

	Company % (Pre-tax NTA)	MSCI %
1 month	(2.3)	(0.5)
3 months	(9.2)	(6.3)
6 months	(13.6)	(12.2)
Calendar year to date	(11.8)	(11.2)
1 year	(17.4)	(15.4)
2 years (compound pa)	4.6	4.8
3 years (compound pa)	6.7	4.7
5 years (compound pa)	6.7	5.2
Since inception (compound p	pa) 7.4	7.3

PAI's returns are calculated after the deduction of fees and expenses, adjusted for taxes paid and any capital flows and assume the reinvestment of dividends. PAI's returns have not been calculated using PAI's share price.

# **INVESTED POSITIONS**<sup>3</sup>

LONG %	CHODT 0/		
_0.10 /0	SHORT %	NET %	CCY %
82.3	(1.0)	81.3	86.8
42.3		42.3	42.3
4.1		4.1	9.4
5.9		5.9	5.9
9.2	(1.0)	8.3	8.5
0.5		0.5	0.5
1.3		1.3	1.3
1.8		1.8	1.8
1.5		1.5	1.5
9.8		9.8	9.7
5.8		5.8	5.8
			13.2
			13.2
82.3	(1.0)	81.3	100.0
17.7	1.0	18.7	
100.0		100.0	100.0
	42.3 4.1 5.9 9.2 0.5 1.3 1.8 1.5 9.8 5.8	42.3 4.1 5.9 9.2 (1.0) 0.5 1.3 1.8 1.5 9.8 5.8 82.3 (1.0) 17.7 1.0	42.3 4.1 5.9 9.2 (1.0) 8.3 0.5 1.3 1.8 1.5 9.8 9.8 5.8  82.3 (1.0) 81.3 17.7 1.0 81.3

Long - 59 stocks, 1 swap Short - 1 swap, 1 index

### **FEES**

1.10% p.a. (excl. GST) of portfolio value\* Management fee:

Performance fee: 15.00% p.a. (excl. GST) of outperformance

over benchmark (MSCI All Country Asia ex

Japan Net Index (A\$))

\*The portfolio value is the market value of the investments in the portfolio after the deduction of fees and expenses, adjusted for taxes, corporate actions and dividends.

# PERFORMANCE GRAPH 2



assume the reinvestment of dividends. PAI's returns have not been calculated using PAI's share price.

TOP TEN POSITIONS<sup>4</sup>

MSĈI

60.1%

STOCK	COUNTRY	INDUSTRY	%
Taiwan Semiconductor	Taiwan	Info Technology	5.4
Samsung Electronics Co	South Korea	Info Technology	4.6
Vietnam Ent Investments	Vietnam	Other	4.0
Tencent Holdings Ltd	China	Comm Services	4.0
ZTO Express Cayman Inc	China	Industrials	3.9
InterGlobe Aviation Ltd	India	Industrials	3.9
Ping An Insurance Group	China	Financials	3.5
SK Hynix Inc	South Korea	Info Technology	3.3
China Resources Land Ltd	China	Real Estate	3.1
Alibaba Group Holding Ltd	China	Cons Discretionary	2.8
		Total	38.3

### INDUSTRY BREAKDOWN<sup>3</sup>

SECTOR	LONG %	SHORT %	NET %
Consumer Discretionary	17.8		17.8
Information Technology	15.7	(1.0)	14.7
Industrials	12.0		12.0
Real Estate	11.9		11.9
Financials	9.3		9.3
Communication Services	4.0		4.0
Consumer Staples	3.5		3.5
Materials	3.4		3.4
Health Care	0.7		0.7
Energy	0.1		0.1
Other	4.0		4.0

Platinum Investment Management Limited ABN 25 063 565 006 AFSL 221935, trading as Platinum Asset Management ("Platinum") is the investment manager of Platinum Asia Investments Limited ("PAI"). This information is general in nature and does not take into account your specific needs or circumstances. You should consider your own financial position, objectives and requirements and seek professional financial advice before making any financial decisions. Numerical figures have been subject to rounding. Neither PAI nor Platinum, guarantee the performance of PAI, the repayment of capital or the payment of income. The market commentary reflects Platinum's views and beliefs at the time of preparation, which are subject to change without notice. No representations or warranties are made by PAI or Platinum as to their accuracy or reliability. To the extent permitted by law, no liability is accepted by PAI or Platinum for any loss or damage as a result of any reliance on this information.

1. & 2. Source: Platinum for portfolio returns and Factset Research Systems for MSCI returns. The returns are calculated relative to the MSCI All Country Asia ex-Japan Net Index in A\$. The investment returns in the line graph are cumulative on A\$20,000 invested in PAI since inception. Past performance is not a reliable indicator of future returns. Platinum does not invest by reference to the weightings of the index. The index is provided

as a reference only.

as a reference only.

3. The "Long %" is the exposure to long securities and long securities/index derivative positions, the "Short %" is the exposure to short securities and short securities/index derivative positions, each as a percentage of PAI's portfolio value. The "Currency %" is the effective currency exposure of PAI's portfolio as a percentage of its portfolio value, taking into account long and short securities, forwards and long and short securities, forwards and long and short securities. For the "Industry breakdown", index positions (whether through ETFs or derivatives) are only included under "Other".

3. and 4. Country classifications for securities reflect Bloomberg's "country of risk" designations, and currency classifications for securities of our country classifications.

# Platinum Asia Investments Limited ASX: PAI

MONTHLY REPORT 31 May 2022

### MARKET UPDATE AND COMMENTARY

♦ Platinum

- Asia basically flat over the month of May.
- China stimulus measures continue, to little effect amid lockdowns.
- An mRNA vaccine is under development in China.

May saw another month of relative stability in Asian markets. Contributors to the portfolio's performance for the month included several of our short positions including an Indian tech outsourcing firm, and the Hong Kong and Korean country indices. Our long position in Korean battery and petrochemical giant LG Chem also contributed to performance. Detractors for the month included many of the largest and highest-quality companies in Asia, including Tencent, Taiwan Semiconductor Manufacturing and SK Hynix, perhaps indicative of ongoing selling by foreigners across Asia.

### China stimulus continues

China is clearly attempting to stimulate its economy. This is apparent in data such as the 'credit impulse': credit growth less nominal GDP, with positive readings indicating increased debt to GDP (please see accompanying chart). May saw further stimulus measures such as tax cuts, loosening of vehicle sales quotas (many Chinese cities restrict the number of cars sold each year) and an acceleration of infrastructure spending (Source: Reuters).

China has been seeking to stimulate its economy since at least November last year, as we have mentioned in previous monthly commentaries. This is unlikely to have any pronounced effect in the presence of ongoing lockdowns, in our view. However, China's zero-Covid policy is unlikely to last forever.

### A Chinese mRNA vaccine is in development

China has been developing an mRNA vaccine since March 2020. During the month, investment team members attended a virtual conference at which the CEO of Everest Biotech and the founder of CanSinoBIO spoke. We would summarise their comments as follows: progress on an mRNA vaccine is being made; there is likely to be several months to go before an mRNA vaccine is available in China; further, sufficient capacity to manufacture at the scale required to roll out a vaccine across China would take several months more; however, by late this year, there could be an mRNA vaccine available in China.

Vice-Premier Liu He, Xi Jinping's most senior economic advisor, made comments supportive of China's tech giants following a symposium with the management of many of China's tech giants. This marks another small step in the months-long thawing of relations with China's tech sector, including public recognition by Chinese officials of the importance of China's tech firms to its economy.


What appears to be building in China is similar to a coiled spring in our view: ongoing economic stimulus; a turning of the credit cycle; and an improving regulatory environment for large, listed firms. This is in marked contrast to the situation in many markets, notably the US, where enormous stimulus measures are being withdrawn, monetary policy tightened and quantitative easing reversed.

What is lacking is a relaxation of China's restrictive policy in regards to Covid given its hitherto failed response to the disease. News of successful vaccine development in Western markets was a major catalyst for improved performance in the wake of the Covid sell-off of 2020. We see no reason why news of a successful mRNA vaccine in China would not have a similar effect, with potentially significant outcomes for China, the region, and indeed, cyclical equities globally.




Source: Chart 1 – IBES consensus, in local currency. Correct as at 6 June 2022.

### Earnings per share growth - Next 12 months



Source: Chart 2 – IBES consensus, in local currency. Correct as at 6 June 2022.



2004 2006 2008 2010 2012 2014 2016 2018 2020 2022

Source: Chart 3 - Bloomberg. From 31/12/2004 to 30/04/2022.